SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus

E-ISSN： 1875-5917|3|4|291-298

ISSN： 1568-0088

Source： Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol.3, Iss.4, 2003-12, pp. : 291-298

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ROS Acts as a Double-Edged Sword in the Pathogenesis of Type 2 Diabetes Mellitus: Is Nrf2 a Potential Target for the Treatment?

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 12, 2011-10 ,pp. : 1082-1092

Bentham Science Publishers

Access to resources Recommend Favorite

Orlistat: In the Prevention and Treatment of Type 2 Diabetes Mellitus

By Keating G.M. Jarvis B.

Drugs, Vol. 61, Iss. 14, 2001-01 ,pp. : 2107-2119

Adis International

Access to resources Recommend Favorite

Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus

By Landgraf R.

Drugs & Aging, Vol. 17, Iss. 5, 2000-11 ,pp. : 411-425

Adis International

Access to resources Recommend Favorite

Orlistat in the treatment of Type 2 diabetes mellitus

By Jneidi Muna Kelley David E

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 599-605

Informa Healthcare

Access to resources Recommend Favorite

Vildagliptin in the treatment of type 2 diabetes mellitus

By Stamataros George Schneider Stephen H

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 12, 2011-08 ,pp. : 1967-1973

Informa Healthcare

Access to resources Recommend Favorite